Shoko Narita, Shintaro Kanda
Abstract
In the treatment of non-small cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) mutations, EGFR-tyrosine kinase inhibitor (EGFR-TKI) is a key drug that can prolong the survival of patients.
OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
In the treatment of non-small cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) mutations, EGFR-tyrosine kinase inhibitor (EGFR-TKI) is a key drug that can prolong the survival of patients.
Key concepts: Epidermal growth factor receptor, Cancer research, Tyrosine-kinase inhibitor, Lung cancer, Tyrosine kinase, Epidermal growth factor, Growth factor receptor inhibitor, Medicine